Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/55155
Title: Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus
Authors: Novak, Glaucia V.
Marques, Mariana
Balbi, Verena
Gormezano, Natali W. S.
Kozu, Katia
Sakamoto, Ana P. [UNIFESP]
Pereira, Rosa M. R.
Terreri, Maria T. [UNIFESP]
Magalhaes, Claudia S.
Guariento, Andressa
Sallum, Adriana M. E.
Marini, Roberto
Leme Ferriani, Virginia Paes
Barbosa, Cassia Maria
Monteiro de Castro, Tania Caroline
Ramos, Valeria C.
Bonfa, Eloisa
Silva, Clovis A.
Keywords: Anti-Ro/SSA autoantibodies
Anti-La/SSB autoantibodies
Sjogren syndrome and childhood-systemic
lupus erythematosus
Multicenter cohort
Issue Date: 2017
Publisher: Elsevier Science Bv
Citation: Autoimmunity Reviews. Amsterdam, v. 16, n. 2, p. 132-135, 2017.
Abstract: Background: To our knowledge there are no studies assessing anti-Ro/SSA and anti-La/SSB autoantibodies in a large population of childhood-systemic lupus erythematosus (cSLE) patients. Methods: This was a retrospective multicenter cohort study performed in 10 Pediatric Rheumatology services, Sao Paulo state, Brazil. Anti-Ro/SSA and anti-La/SSB antibodies were measured by enzyme linked immunosorbent assay (ELISA) in 645 cSLE patients. Results: Anti-Ro/SSA and anti-La/SSB antibodies were evidenced in 209/645 (32%) and 102/645 (16%) of cSLE patients, respectively. Analysis of cSLE patients with and without anti-Ro/SSA antibodies revealed higher frequencies of malar rash (79% vs. 71%, p = 0.032), photosensitivity (73% vs. 65%, p = 0.035), cutaneous vasculitis (43% vs. 35%, p = 0.046) and musculoskeletal involvement (82% vs. 75%, p = 0.046) in spite of long and comparable disease duration in both groups (4.25 vs. 4.58 years, p = 0.973). Secondary Sjogren syndrome was observed in only five patients with this antibody (2.5% vs. 0%, p = 0.0035), two of them with concomitant anti-La/SSB. The presence of associated autoantibodies: anti-Sm (50% vs. 30%, p < 0.0001), anti-RNP (39% vs. 21%, p < 0.0001) and anti-ribossomal P protein (46% vs. 21%, p = 0.002) was also significantly higher in patients with anti-Ro/SAA antibodies. Further evaluation of cSLE patients with the presence of anti-La/SSB antibodies compared to those without these autoantibodies showed that the frequency of alopecia (70% vs. 51%, p = 0.0005), anti-Sm (59% vs. 31%, p < 0.0001) and anti-RNP (42% vs. 23%, p < 0.0001) were significantly higher in the former group. Conclusions: Our large multicenter cohort study provided novel evidence in cSLE that anti-Ro/SSA and/or anti-La/SSB antibodies were associated with mild manifestations, particularly cutaneous and musculoskeletal. Secondary Sjogren syndrome was rarely observed in these patients, in spite of comparable frequencies of anti-Ro/SSA and/or anti-La/SSB reported for adult SLE. (C) 2016 Elsevier B.V. All rights reserved.
URI: https://repositorio.unifesp.br/handle/11600/55155
ISSN: 1568-9972
Other Identifiers: http://dx.doi.org/10.1016/j.autrev.2016.12.004
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.